Carvedilol Drug Market

Carvedilol Drug Market: Introduction

Carvedilol is a non-selective adrenergic blocker used in clinically stable individuals to treat heart failure with reduced ejection fraction (HFrEF), hypertension, and left ventricular dysfunction after a myocardial infarction (MI). Carvedilol's off-label uses include stable angina, atrial fibrillation, cirrhotic esophageal variceal hemorrhage prevention, and ventricular arrhythmias. This exercise examines the mechanism of action, adverse event profile, toxicity, dosage, pharmacodynamics, and monitoring of carvedilol, which is important for clinicians and other members of the inter-professional team in order to use carvedilol appropriately for the specified conditions.

Global Carvedilol Drug Market: Drivers, Retrains, and Trends

• Increase in patient pool of cardiovascular diseases (CVDs) is one of the primary factors driving the global carvedilol drug market. Sedentary lifestyles, junk food intake, and mental stress are all linked to the development of CVDs.
• According to the World Health Organization, cardiovascular disease is the leading cause of death globally in 2019, accounting for an estimated 17.9 million deaths each year. Hence, the large target population is projected to boost the growth of the global carvedilol drug market. Increase in the geriatric population also contributes to the rise in CVD cases globally.
• Surge in number of patients suffering from hypertension is also anticipated to drive the global carvedilol drug market
• However, rigorous regulations and side effects of cardiovascular medications are expected to hamper the growth of the global carvedilol drug market. Moreover, patent expiration of several blockbuster medications is likely to restrain the global carvedilol drug market. Increase in mergers and acquisitions among pharmaceutical firms and new product launches are the key factors driving the global carvedilol drug market.
• According to the WHO, cardiovascular diseases accounted for 17.7 million deaths in 2015. Increase in government initiatives to improve awareness about various types of cardiovascular diseases and rise in R&D spending for innovative cardiovascular medicines, are projected to boost market growth. Moreover, changes in lifestyle have increased the prevalence of obesity, which has led to a surge in the global incidence of cardiovascular diseases. However, the difficult regulatory clearance procedure for medicines, high treatment cost, and adverse effects associated with cardiovascular treatments hamper market growth.
• Mergers and acquisitions, product launches, and partnerships are the strategies adopted by leading players to retain their leadership positions. In February 2019, Amgen, Cytokinetics, and Servier launched METEORIC-HF, the second phase III clinical study of omecamtiv mecarbil in heart failure patients.
• Universities and educational institutions are working with the industry to produce viable medicines for the treatment of heart failure. For example, Yale University has undertaken a phase II clinical research in collaboration with Boehringer Ingelheim, a modest pilot proof of concept study to not only show the existence of, but also probe the mechanism.
• Carvedilol, a beta-blocker, has been proven in in-vitro and in-vivo to inhibit skin carcinogenesis. Researchers created a carvedilol-loaded transfersome for skin-targeted administration, as systemic absorption of the beta-blocker could cause cardiovascular problems. Transfersomes were created and described by varying the ratios of phospholipids and surfactants. These findings suggest that transfersome is a potential carvedilol topical administration method for reducing UV-induced skin damage and carcinogenesis.

North America held Major Share of Global Carvedilol Drug Market

North America dominated the global carvedilol drug market in 2020. This is attributed to higher awareness about various cardiac problems in the region. The U.S. was the largest market for cardiovascular medicines in North America, followed by Canada. Germany, the U.K., Spain, Italy, and France account for major share of the carvedilol drug market in Europe. However, the market in Asia Pacific is anticipated to grow at a rapid pace in the next five years. This is because a number of companies are establishing R&D centers in the region. Less restrictive salaries and the availability of trained personnel induce manufacturers to invest in the region. Moreover, rise in awareness drives the carvedilol drug market in Asia Pacific.

Key Players in Global Carvedilol Drug Market

• Novartis AG
• AstraZeneca plc
• GlaxoSmithKline plc
• Bristol-Myers Squibb
• Mylan N.V.
• Johnson & Johnson
• Bayer AG
• Merck & Co., Inc.
• Sanofi
• Ranbaxy
• Other Players

Global Carvedilol Drug Market: Research Scope

Global Carvedilol Drug Market, by Product Type

• Injectables
• Capsules
• Tablets

Global Carvedilol Drug Market, by Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Carvedilol Drug Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa